Combined thromboxane A2synthetase inhibition and receptor blockade are effective in preventing spontaneous and epinephrine-induced canine coronary cyclic flow variations

This publication has 46 references indexed in Scilit:

• Serotonin S2and thromboxane A2-prostaglandin H2receptor blockade provide protection against epinephrine-induced cyclic flow variations in severely narrowed canine coronary arteries
  Journal of the American College of Cardiology, 1989
• Local platelet activation causes vasoconstriction of large epicardial canine coronary arteries in vivo. Thromboxane A2 and serotonin are possible mediators.
  Circulation, 1989
• Platelet Activation in Unstable Coronary Disease
  New England Journal of Medicine, 1986
• Speculation regarding mechanisms responsible for acute ischemic heart disease syndromes
  Journal of the American College of Cardiology, 1986
• Potentiation with epinephrine of macaque platelet aggregation by other agonists: Implications for studies on human atherosclerosis
  Thrombosis Research, 1986
• Conversion from chronic to acute coronary artery disease: Speculation regarding mechanisms
  The American Journal of Cardiology, 1984
• Platelet activation by circulating levels of hormones: A possible link in coronary heart disease
  Thrombosis Research, 1984
• The facilitating effects of adrenaline on platelet aggregation
  Prostaglandins, Leukotrienes and Medicine, 1982
• Release of Prostaglandins and Thromboxane into the Coronary Circulation in Patients with Ischemic Heart Disease
  New England Journal of Medicine, 1981
• Effects of adrenaline on human blood platelets
  The Journal of Physiology, 1967